|
Home >> Development Pipeline |
TP1001 - Inflammation
Inflammation lies at the heart of many disease states, including cancer, joint disease, skin disease, asthma, intestinal disease, and autoimmune disease. An unchecked inflammatory response can destroy tissues, cause pain and inhibit the natural function of many tissues and organs. Mediators of inflammation include the tumor necrosis family (TNF), neutrophil contents, the CXCR family, and cytokines such as IL-6 and IL-10.
TP1001 is an oral anti-inflammatory agent. In pre-clinical animal models of inflammation, TP1001 was superior to currently-marketed inflammation therapies. TP1001 has completed a Phase IIa clinical study in inflammation and pain, where it demonstrated superior efficacy to placebo and active comparators. The compound is oral and well tolerated. Tragara plans to move this program into Phase IIb clinical trials in 2008.
|
TP2001 - Oncology
Cancer is driven by abnormalities in a number of normal cell processes, mediated by certain signaling pathways. Abnormalities in these pathways leading to oncogenic transformation include the HIF-1, VEGF, VEGF-R and PDGF systems for angiogenesis; the EGFR, HER2/neu, Bcr/Abl for growth control and differentiation; the intrinsic and extrinsic pathways for apoptosis; the integrin and metalloproteinase systems for tissue invasion and metastasis. Further, multiple pathways are often deregulated in cancer cells due to the inherent genetic instability of these cells. Effective treatments for cancer will address these oncogenic signaling pathways as well as the redundancy of survival signals present in cancer cells.
TP2001 is an oral anti-cancer treatment designed to act against a well-defined cancer pathway that affects many of the routes of cancer pathogenesis mentioned above. In pre-clinical cancer models it has shown superiority to compounds with similar mechanisms of action and synergy in combination with cisplatin. TP2001 is currently in Phase 1 clinical testing for the treatment of cancer at multiple clinical centers in the United States.
|
TP3001 - Biomarker Diagnostic for Targeted Therapy
The use of molecular biomarkers in the diagnosis and treatment of disease has become an important facet of modern drug development. Biomarker-based diagnostic products are frequently used beyond initial diagnosis to select patients for specific therapies and monitor disease response to the therapy.
TP3001 is a proprietary diagnostic product based upon a key molecular biomarker, under development for use initially in oncology. TP3001 is currently in early stage development. |
|
|
